Morgan Stanley Maintains Equal-Weight on Arrowhead Pharma, Raises Price Target to $81

Benzinga · 5d ago
Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Equal-Weight and raises the price target from $48 to $81.